Emerging-Market Savvy Makes GlaxoSmithKline plc A Clear Buy For Me

Roland Head explains the massive opportunity that’s hidden in the GlaxoSmithKline plc (LON:GSK) 2012 sales figures.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) chief executive Andrew Witty was quoted in the Indian press last week as being supportive of lower prices for patented drugs in India.

Indeed, Witty sounded like a Fool when he told the The Economic Times that “the problem is too many people get obsessed with short-term volatility … you have to look at long term.”

Of course, Andrew Witty is a savvy businessman and he knows that by adopting a reasonable and accommodative approach to the Indian government’s requirements, he is likely to smooth the regulatory path for future product launches in India, which has a population of 1.2bn people (the population of the entire EU is just 500m).

One mistake is not a failure

Glaxo’s emerging markets strategy has taken a painful hit from the China bribery scandal, but that’s all it is.

I firmly believe that Glaxo’s emerging market growth will help fund the dividend income from my Glaxo shares for many years to come.

An 88-bagging opportunity

According to Glaxo, the overall pharmaceutical market in its Emerging Markets Asia Pacific (EMAP) region grew by an average of 14.7% per year between 2007 and 2012.

Despite this, 2012’s EMAP total of £112bn was just half the £221bn value of the US pharmaceutical market in 2012 — even though India alone has a population four times larger than the USA.

Glaxo’s own EMAP sales grew by 10% in 2012, and I was interested to learn that the biggest growth was in vaccines (up 14%) and what the company calls ‘innovative brands’ (up 15%). These are the two areas in which I would expect to see biggest growth in emerging markets, as rising personal income and increased tax revenues mean that spending on public health and modern treatments rises dramatically.

Although emerging market healthcare spending may never reach the elevated levels seen in the US, it’s worth noting that in 2012, Glaxo’s Indian sales were just 25 pence per head of population, while in the US, they were £22 — that’s 88 times more.

If that’s not a growth opportunity, then I’m not sure what is.

What if I’m wrong?

I have a substantial part of my own portfolio invested in Glaxo shares, because I cannot see any scenario — barring a global catastrophe or war — that can stop the rising tide of socio-economic progress in emerging markets, which in turn should mean rising sales for Glaxo.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Roland owns shares in GlaxoSmithKline. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 FTSE income stocks investors should consider buying in April

Income stocks are a great way to build wealth. Our writer details two picks she believes investors should consider snapping…

Read more »

Investing Articles

What might the 5-year price chart tell us about BT shares?

Christopher Ruane considers what clues the long-term performance of BT shares might offer him about business performance and whether to…

Read more »